Metandienone, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act. Metandienone was introduced and formerly sold primarily under the brand name Dianabol. The former synonym should not be confused with methylandrostenolone, which is another name for a different AAS known as metenolone. As with other 17α-alkylated AAS, metandienone may be hepatotoxic, especially with prolonged use of high doses. As the CIBA product Dianabol, metandienone quickly became the first widely used AAS among professional and amateur athletes, and remains the most common orally active AAS for non-medical use. In case a hereditary predisposition exists, metandienone can cause a possible balding. Methandienone 10mg has a strong effect on the liver that why a long-term therapy is liver-toxic. Methandienone administration in women can cause virilization symptoms. Also, it is used in the treatment of tuberculosis, osteomyelitis, asthma, hepatitis. Using a semi-targeted approach including the synthesis of reference compounds, two diastereomeric substances, viz. There are many known cases of doping in sports with metandienone by professional athletes. It has also been marketed under a variety of other brand names including Anabol, Averbol, Chinlipan, Danabol, Dronabol, Metanabol, Methandon, Naposim, Reforvit-B, and Vetanabol among others. Non-medical use was outlawed in the U.S. under the Anabolic Steroids Control Act of 1990. The elimination half-life of metandienone is about 3 to 6 hours. It has very low affinity for human serum sex hormone-binding globulin (SHBG), about 10% of that of testosterone and 2% of that of DHT. As such, it can cause side effects such as gynecomastia and fluid retention. Methandienone binds to and activates the androgen receptor (AR) in order to exert its effects. Estrogenic side effects such as gynecomastia and fluid retention can also occur. Unlike methyltestosterone, owing to the presence of its C1(2) double bond, metandienone does not produce 5α-reduced metabolites. Proposed metabolism of methyltestosterone (black, … Chemical structures of phase I metabolites of methyltestosterone reported in the literature. The drug is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT), and has strong anabolic effects and moderate androgenic effects. Reaction scheme for 17α-hydroxymethyl-17β-methyl-18-nor-5ξ-androst-13-en-3ξ-ol steroids. It is also referred to as methandrostenolone and as dehydromethyltestosterone. The primary urinary metabolites are detectable for up to 3 days, and a recently discovered hydroxymethyl metabolite is found in urine for up to 19 days after a single 5 mg oral dose. The drug is also candy96.fun the 17α-methylated derivative of boldenone (δ1-testosterone) and the δ1 analogue of methyltestosterone (17α-methyltestosterone). Metandienone, also known as 17α-methyl-δ1-testosterone or as 17α-methylandrost-1,4-dien-17β-ol-3-one, is a synthetic androstane steroid and a 17α-alkylated derivative of testosterone. Metandienone, also known as methandienone or methandrostenolone and sold under the brand name Dianabol (D-Bol) among others, is an androgen and anabolic steroid (AAS) medication which is mostly no longer prescribed. Metandienone and methyltestosterone are orally active anabolic-androgenic steroids with a 17α-methyl structure that are prohibited in sports but are frequently detected in anti-doping analysis. While the rate of aromatization is reduced relative to that for testosterone or methyltestosterone, the estrogen produced is metabolism-resistant and hence metandienone retains moderate estrogenic activity. Proposed metabolism of methyltestosterone (black, 18 ) and metandienone (red, 12 ) to… Additionally, 3α,5β-tetrahydro-epi-methyltestosterone was identified in the urines of both administrations besides the classical metabolites included in the screening procedures. 17α-hydroxymethyl-17β-methyl-18-nor-5β-androst-13-en-3α-ol and its 5α-analog, were identified following an administration of methyltestosterone. It is currently a controlled substance in the United States and United Kingdom and remains popular among bodybuilders. Metandienone was originally developed in 1955 by CIBA and marketed in Germany and the United States. Androgenic side effects such as oily skin, acne, seborrhea, increased facial/body hair growth, scalp hair loss, and virilization may occur. Metandienone is used for physique- and performance-enhancing purposes by competitive athletes, bodybuilders, and powerlifters. Metandienone was provided in the form of 2.5, 5 and 10 mg oral tablets. Metandienone is readily available without a prescription in certain countries such as Mexico, and is also manufactured in some Asian countries. When entering the cell nucleus, it stimulates the genetic apparatus of the cell, causing the synthesis of DNA, RNA, and structural proteins, activates the enzymes of tissue respiration chain and enhancing tissue respiration, oxidative phosphorylation, ATP synthesis and intracellular aggregation macroergic. Due to its short action time 3.2 to 4.5 hours, it is necessary to administrate it at least twice a day in order to maintain the necessary concentration of methandienone in the blood. Metandienonum is not indicated to be used is there is hypersensitivity to the drug, prostate cancer, breast carcinoma in women with hypercalcemia, CPI, severe atherosclerosis,breast cancer in men, hepatic and renal function, acute and chronic prostatitis, pregnancy and lactation.
